Brief: Greenwich Lifesciences Provides Clinical Updates On FLAMINGO-01
20/07/2026 11:23
BRIEF-Greenwich Lifesciences Provides Clinical Updates On FLAMINGO-01 July 20 (Reuters) - Greenwich Lifesciences Inc GLSI.O:
GREENWICH LIFESCIENCES PROVIDES CLINICAL UPDATES ON FLAMINGO-01
GREENWICH LIFESCIENCES - FLAMINGO-01 DSMB RECOMMENDS STUDY CONTINUE WITHOUT MODIFICATION IN MAY 2026
GREENWICH LIFESCIENCES - FLAMINGO-01 STEERING COMMITTEE ENDORSES STUDY SIZE INCREASE AND ACCELERATED ENROLLMENT
GREENWICH LIFESCIENCES - FLAMINGO-01 PHASE 3 OBJECTIVES MET FOLLOWING FDA AND EMA REVIEW
GREENWICH LIFESCIENCES - Q2 2026 BURN RATE EXPECTED AT $2 MILLION; CASH BALANCE $8.90 MILLION AS OF JUNE 30, 2026
Source text: ID:nGNX6DWTPp
Further company coverage: GLSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio